Corticostéroïdes et syndrome de détresse respiratoire aigu

Chercheurs-boursiers cliniciens- Junior 1 | Concours 2012-2013


François Lamontagne

Centre de recherche clinique Étienne-Le Bel du CHUS

 

Domaine : Santé circulatoire et respiratoire

Too often, medical practice does not rely on strong scientific evidence. When this happens, even when a consensus exists among experts, patients may receive therapies that are harmful. There exist many examples of medical interventions once considered standard of care that were subsequently completely invalidated by rigorous research. I propose a program of research that will measure the effects of a common intervention, the administration of a medication related to cortisone, in the context of a respiratory inflammatory condition named the acute respiratory distress syndrome (ARDS).

According to recent data, different respiratory inflammatory syndromes, ARDS being the most severe, affect 79 / 100 000 individuals yearly. This means that in a population of 8 000 000 individuals like that of Quebec, more than 6 000 individuals suffer from such a syndrome every year. Risk of death varies between 30 and 50% but, unfortunately, even those that survive remain affected for a long time by various deficits that considerably limit their quality of life.

Corticosteroids (like cortisone) are potent anti-inflammatory agents used for a number years to treat inflammatory respiratory syndromes like ARDS. Unfortunately, current scientific evidence cannot determine whether these medications are overall beneficial or harmful. We have put together a vast program of research that will rigorously measure the effects of corticosteroids on ARDS mortality and lead to more efficacious and safer healthcare.